CAJ | 학술논문

目的：：评价重组人白介素-11(Ⅰ)[rhIL-11(Ⅰ)]和重组人促血小板生成素(rhTPO)治疗吉西他滨联合化疗相关血小板减少的效果和经济学意义。方法：采用回顾性分析法,收集2011年6月~2014年6月接受吉西他滨化疗导致血小板减少而使用rhIL-11(Ⅰ)或rhTPO治疗的58例肺癌住院患者,比较两种升血小板药物的疗效,并做经济学评价。结果： rhIL-11(Ⅰ)组患者化疗后血小板最低值高于rhTPO组(P<0.01)；治疗后血小板持续减少时间短于rhTPO组(P<0.01)。但两组血小板达标比例差异无统计学意义(P>0.05)。采用最小成本分析,rhIL-11(Ⅰ)组平均成本低于rhTPO组(P<0.01), rhIL-11(Ⅰ)组中不论接受GP、GC或其他以吉西他滨为基础的化疗方案,患者的平均成本均低于rhTPO组。结论：rhIL-11(Ⅰ)用于以吉西他滨为基础联合化疗治疗的肺癌患者后引起的血小板减少效果不劣于rhTPO,且在经济成本上具有一定优势。
목적：：평개중조인백개소-11(Ⅰ)[rhIL-11(Ⅰ)]화중조인촉혈소판생성소(rhTPO)치료길서타빈연합화료상관혈소판감소적효과화경제학의의。방법：채용회고성분석법,수집2011년6월~2014년6월접수길서타빈화료도치혈소판감소이사용rhIL-11(Ⅰ)혹rhTPO치료적58례폐암주원환자,비교량충승혈소판약물적료효,병주경제학평개。결과： rhIL-11(Ⅰ)조환자화료후혈소판최저치고우rhTPO조(P<0.01)；치료후혈소판지속감소시간단우rhTPO조(P<0.01)。단량조혈소판체표비례차이무통계학의의(P>0.05)。채용최소성본분석,rhIL-11(Ⅰ)조평균성본저우rhTPO조(P<0.01), rhIL-11(Ⅰ)조중불론접수GP、GC혹기타이길서타빈위기출적화료방안,환자적평균성본균저우rhTPO조。결론：rhIL-11(Ⅰ)용우이길서타빈위기출연합화료치료적폐암환자후인기적혈소판감소효과불렬우rhTPO,차재경제성본상구유일정우세。
Objective:To evaluate the efficacy and pharmacoeconomics of rhIL-11(Ⅰ) and rhTPO in the treatment of thrombocy-topenia caused by gemcitabine chemotherapy in lung cancer patients. Methods:A retrospective analysis was used. Totally 58 hospital-ized lung cancer patients who suffered thrombocytopenia caused by gemcitabine chemotherapy and treated with rhIL-11(Ⅰ) or rhTPO from June 2011 to June 2014 were involved in the study, and the efficacy and pharmacoeconomics of rhIL-11(Ⅰ) and rhTPO were e-valuated and compared. Results:The lowest platelet value after the chemotherapy in rhIL-11(Ⅰ) group was higher than that in rhTPO group (P<0. 01), and the platelet decrease time in rhIL-11(Ⅰ) group was shorter than that in rhTPO group (P<0. 01), while the platelet qualified rate of the two groups showed no statistically significant difference (P>0. 05). The results of cost-minimization anal-ysis showed that the average cost of rhIL-11(Ⅰ) group was lower than that of rhTPO group(P<0. 01), furthermore, the average cost of the patients with GP, GC or the other gemcitabine chemotherapy regimens in rhIL-11 (Ⅰ) group was lower than that in rhTPO group. Conclusion:The effect of rhIL-11 (Ⅰ) in the treatment of thrombocytopenia caused by gemcitabine based-chemotherapy in lung cancer patients is not inferior to that of rhTPO, and shows certain advantages in economic cost.